Safflower oil

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Name
Safflower oil
Accession Number
DB09446
Type
Biotech
Groups
Approved, Investigational
Description

Safflower (Carthamus tinctorius L) is a herbaceous plant in the Asteraceae family. Extracted from the seeds of safflowers, safflower oil is a rich source of various saturated fatty acids, monounsaturated fatty acid (oleic acid) or essential n-6 polyunsaturated fatty acid (PUFA) linoleic acid 1,3, depending on the flower type. Safflower oil with a higher content of polyunsaturated fatty acids is more commonly used as an edible oil. The constituents of safflower oil also include alpha-tocopherol, gamma-tocopherol, and mixed Tocopherol 4. Safflower oil is approved for use as an indirect additive in food contact substances and is readily available as a food ingredient. Gamma linolenic acid (GLA) safflower oil is marketed as an over-the-counter dietary supplement.

Synonyms
  • Carthamus tinctorius seed oil
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Carthaphy CapSafflower oil (912 mg) + Pyridoxine hydrochloride (.5 mg)CapsuleOralPhyto Health Corporation1973-12-312003-11-27Canada
Liposyn IISafflower oil (10 g/100mL) + Egg phospholipids (1.2 g/100mL) + Soybean oil (10 g/100mL)Injection, emulsionIntravenousHospira, Inc.1984-08-272011-02-01Us
Liposyn IISafflower oil (5 g/100mL) + Egg phospholipids (1.2 g/100mL) + Soybean oil (5 g/100mL)Injection, emulsionIntravenousHospira, Inc.1984-08-272011-02-01Us
Liposyn II 10%Safflower oil (5 %) + Egg phospholipids (0.9 %) + Soybean oil (5 %)EmulsionIntravenousHospira, Inc.1987-12-312014-08-01Canada
Liposyn II 20%Safflower oil (10 %) + Egg phospholipids (1.2 %) + Soybean oil (10 %)EmulsionIntravenousHospira, Inc.1987-12-312014-08-01Canada
Liposyn II Inj 10%Safflower oil (5.0 g) + Egg phospholipids (700 mg) + Soybean oil (5.0 g)EmulsionIntravenousHospira, Inc.1992-01-012014-08-01Canada
Categories
UNII
65UEH262IS
CAS number
8001-23-8

Pharmacology

Indication

No approved therapeutic indications.

Pharmacodynamics

Safflower oil contains n-6 polyunsaturated fatty acids (PUFAs) such as conjugated linoleic acid (CLA) which may have lipid-lowering and anti-inflammatory actions, as well as tocopherols. In a study of post-menopausal, obese women with type 2 diabetes, safflower oil supplementation was associated with improved metabolic endpoints including HbA1c, fasting glucose, insulin sensitivity estimated by QUICKI, HDL cholesterol, CRP, and adiponectin 1.

Mechanism of action

Linoleic acid in safflower oil may decrease serum cholesterol levels by activating hepatic uptake and biliary excretion of serum cholesterol 2. Tocopherol in safflower oil is a radical scavenger with antioxidant properties.

Absorption

Fatty acids and tocopherol from safflower oil are expected to undergo absorption within the digestive tract.

Volume of distribution

No pharmacokinetic data available.

Protein binding

No pharmacokinetic data available.

Metabolism

No pharmacokinetic data available.

Route of elimination

No pharmacokinetic data available.

Half life

No pharmacokinetic data available.

Clearance

No pharmacokinetic data available.

Toxicity

The LD50 in rats is >5.0 g/kg following oral administration and >50 g/kg following intraperitoneal administration 5.

Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
Not Available
Food Interactions
Not Available

References

General References
  1. Asp ML, Collene AL, Norris LE, Cole RM, Stout MB, Tang SY, Hsu JC, Belury MA: Time-dependent effects of safflower oil to improve glycemia, inflammation and blood lipids in obese, post-menopausal women with type 2 diabetes: a randomized, double-masked, crossover study. Clin Nutr. 2011 Aug;30(4):443-9. doi: 10.1016/j.clnu.2011.01.001. Epub 2011 Feb 3. [PubMed:21295383]
  2. Sato M, Yoshida S, Nagao K, Imaizumi K: Superiority of dietary safflower oil over olive oil in lowering serum cholesterol and increasing hepatic mRnas for the LDL receptor and cholesterol 7alpha-hydroxylase in exogenously hypercholesterolemic (exHC) rats. Biosci Biotechnol Biochem. 2000 Jun;64(6):1111-7. doi: 10.1271/bbb.64.1111. [PubMed:10923778]
  3. Cox C, Mann J, Sutherland W, Chisholm A, Skeaff M: Effects of coconut oil, butter, and safflower oil on lipids and lipoproteins in persons with moderately elevated cholesterol levels. J Lipid Res. 1995 Aug;36(8):1787-95. [PubMed:7595099]
  4. Masterjohn C: The anti-inflammatory properties of safflower oil and coconut oil may be mediated by their respective concentrations of vitamin E. J Am Coll Cardiol. 2007 May 1;49(17):1825-6. doi: 10.1016/j.jacc.2007.04.001. Epub 2007 Apr 16. [PubMed:17466237]
  5. SAFFLOWER OIL - National Library of Medicine HSDB Database - Toxnet - NIH [Link]
External Links
Wikipedia
Safflower_oil
MSDS
Download (47.2 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedTreatmentAsthma, Allergic1
2RecruitingTreatmentAirway Inflammation / Asthma Bronchial1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
CapsuleOral
Injection, emulsionIntravenous
EmulsionIntravenous
Prices
Not Available
Patents
Not Available

Properties

State
Liquid
Experimental Properties
PropertyValueSource
boiling point (°C)338-366National Library of Medicine HSDB Database
water solubilityInsolubleNational Library of Medicine HSDB Database

Taxonomy

Classification
Not classified

Drug created on November 30, 2015 12:10 / Updated on June 04, 2019 07:12